| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
(±)-BAY-1251152 is a racemic mixture of BAY-1251152 which is a novel, potent and highly selective PTEF/CDK9 inhibitor. BAY-1251152 exhibits high permeability, no efflux, enhanced selectivity against CDK2, and significantly increased biochemical (IC50 CDK9 = 3 nM) and cellular potency (IC50 MOLM13 = 29 nM). BAY 1251152's high solubility and much lower therapeutic dose allow for the intended intravenous application. BAY 1251152 exhibited remarkable effectiveness when administered intravenously (i.v.) to mice and rats in xenograft models, such as MOLM13. In Phase I studies (NCT02635672; NCT02745743), BAY 1251152 is presently being assessed for safety, tolerability, pharmacokinetics, and initial pharmacodynamic biomarker response in patients with advanced cancer. The transcription of myc and Mcl-1, two short-lived anti-apoptotic survival proteins, is mediated by PTEFb/CDK9 and is essential for the growth and survival of cancer cells in a variety of tumor types, including AML. Furthermore, the development of chemotherapy resistance is significantly influenced by these survival proteins.
| References | |
|---|---|
| Additional Infomation |
See also: Enitociclib (annotation moved to).
|
| Molecular Formula |
C19H18F2N4O2S
|
|---|---|
| Molecular Weight |
404.433629512787
|
| Exact Mass |
404.111
|
| Elemental Analysis |
C, 56.43; H, 4.49; F, 9.40; N, 13.85; O, 7.91; S, 7.93
|
| CAS # |
1610358-53-6
|
| Related CAS # |
Enitociclib;1610358-56-9;(-)-Enitociclib;1610358-59-2
|
| PubChem CID |
74767009
|
| Appearance |
White to light yellow solid powder
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YZCUMZWULWOUMD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18F2N4O2S/c1-27-17-8-13(20)3-4-14(17)15-9-19(24-10-16(15)21)25-18-7-12(5-6-23-18)11-28(2,22)26/h3-10,22H,11H2,1-2H3,(H,23,24,25)
|
| Chemical Name |
5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-[4-[(methylsulfonimidoyl)methyl]pyridin-2-yl]pyridin-2-amine
|
| Synonyms |
(±)-BAY-1251152; (±)-BAY 1251152; (±)-BAY1251152; (-)-BAY-1251152; BAY-1251152; BAY 1251152; BAY1251152; (+)-BAY-1251152
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~123.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4726 mL | 12.3631 mL | 24.7262 mL | |
| 5 mM | 0.4945 mL | 2.4726 mL | 4.9452 mL | |
| 10 mM | 0.2473 mL | 1.2363 mL | 2.4726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA